Figure 4

To test the potential use of erythrocytes as biomarkers, we identified the known morbid SNPs and drug targets of erythrocyte enzymes account for in the reconstructed network. 142 morbid SNPs were identified with the majority dealing with non-erythrocyte related pathologies (see Table 1). In addition, over 230 FDA-approved, FDA-withdrawn, and experimental drugs have known protein targets in the human erythrocyte.